Evidence map›Paper›PMID 35807265›Full record

ArticleMolecules (Basel, Switzerland)2022

Design, Synthesis and Biological Evaluation of 1,3,5-Triazine Derivatives Targeting hA

Sujin Park, Yujin Ahn, Yongchan Kim, Eun Joo Roh, Yoonji Lee, Chaebin Han, Hee Min Yoo, Jinha Yu

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Adenosine receptors in breast cancer.Molecular biology reports · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Sujin ParkCollege of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.
Yujin AhnBiometrology Group, Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Korea.ORCID 0000-0003-4632-031X
Yongchan KimBiomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea.
Eun Joo RohBiomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea.
Yoonji LeeCollege of Pharmacy, Chung-Ang University, Seoul 06974, Korea.ORCID 0000-0002-2494-5792
Chaebin HanCollege of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.
Hee Min YooBiometrology Group, Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Korea.ORCID 0000-0002-5951-2137
Jinha YuCollege of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea.ORCID 0000-0002-0495-5686
Ewha Womans University · KRKorea Institute of Science and Technology · KRKorea Research Institute of Standards and Science · KRChung-Ang University · KR

Funding

Establishment of measurement standards for Chemistry and Radiation KRISS-2022-GP2022-0003National Research Foundation of Korea 2020R1A4A4079494National Research Foundation of Korea 2021M3C1C3097638National Research Foundation of Korea 2022R1C1C1004804
6 · The paper itself

Abstract

Adenosine mediates various physiological activities in the body. Adenosine receptors (ARs) are widely expressed in tumors and the tumor microenvironment (TME), and they induce tumor proliferation and suppress immune cell function. There are four types of human adenosine receptor (hARs): hA

Indexed as

PyrimidinesReceptor, Adenosine A2AHumansMolecular Docking SimulationReceptor, Adenosine A3Structure-Activity RelationshipTriazinesPyrimidinesReceptor, Adenosine A2AReceptor, Adenosine A3Triazines1,3,5-triazineadenosine receptorantitumor agentsdual ligandmolecular docking

Identifiers

PMID35807265
PMCPMC9268102
OpenAlexW4283324317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.